Zimmer Biomet Holdings Inc (ZBH) : Hourglass Capital reduced its stake in Zimmer Biomet Holdings Inc by 4.56% during the most recent quarter end. The investment management company now holds a total of 68,680 shares of Zimmer Biomet Holdings Inc which is valued at $8,883,071 after selling 3,285 shares in Zimmer Biomet Holdings Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Zimmer Biomet Holdings Inc makes up approximately 2.05% of Hourglass Capital’s portfolio.
Other Hedge Funds, Including , Sivik Global Healthcare boosted its stake in ZBH in the latest quarter, The investment management firm added 10,000 additional shares and now holds a total of 60,000 shares of Zimmer Biomet Holdings Inc which is valued at $7,884,000. Zimmer Biomet Holdings Inc makes up approx 3.69% of Sivik Global Healthcare’s portfolio.Blackhill Capital Inc reduced its stake in ZBH by selling 2,300 shares or 1.95% in the most recent quarter. The Hedge Fund company now holds 115,350 shares of ZBH which is valued at $15,156,990. Zimmer Biomet Holdings Inc makes up approx 2.43% of Blackhill Capital Inc’s portfolio.Thompson Investment Management reduced its stake in ZBH by selling 2,655 shares or 7.73% in the most recent quarter. The Hedge Fund company now holds 31,685 shares of ZBH which is valued at $4,132,675. Zimmer Biomet Holdings Inc makes up approx 0.81% of Thompson Investment Management’s portfolio. Donald L. Hagan sold out all of its stake in ZBH during the most recent quarter. The investment firm sold 600 shares of ZBH which is valued $74,688.
Zimmer Biomet Holdings Inc closed down -0.24 points or -0.19% at $127.78 with 10,24,246 shares getting traded on Friday. Post opening the session at $127.28, the shares hit an intraday low of $126.82 and an intraday high of $127.96 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.97. The company had revenue of $1934.00 million for the quarter, compared to analysts expectations of $1898.18 million. The company’s revenue was up 65.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. SunTrust Initiated Zimmer Biomet Holdings Inc on Aug 11, 2016 to “Buy”, Price Target of the shares are set at $155.Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 150 from a previous price target of $143 .Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.